Those in the CBT-I group who experienced sustained remission of insomnia had significant lowering of p16INK4a gene expression while those in the control group who had sustained insomnia over the 2-year interval exhibited increases in p16INK4a. The gene discussed is CDKN2A; the disease is insomnia measurement.